Please provide your email address to receive an email when new articles are posted on . The FDA approved a mapping and dual-energy catheter ablation system for treatment of persistent AF. The system ...

In this case, we describe a case of atypical slow-slow AVNRT in a patient with dextrocardia and an unusual His bundle position in the low posterior septum of the morphologic right atrium. The His ...

Enrollment completed ahead of schedule in the global IDE for Abbott (ABT)'s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ ...

Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...

Only a few months after Medtronic completed its acquisition of cardiac device maker Affera, the nearly billion-dollar buyout is already paying off. A dual-use catheter originally developed by Affera ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a navigation-enabled ablation catheter for the treatment of ...

Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and ...

A team from Lenox Hill Hospital in New York City has become one of the first in the U.S. to successfully treat atrial fibrillation with a three-in-one mapping and ablation system. The Affera system ...

Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a ...